Last reviewed · How we verify
Utidelone in combination with capecitabine — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Utidelone in combination with capecitabine (Utidelone in combination with capecitabine) — Biostar Pharma, Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Utidelone in combination with capecitabine TARGET | Utidelone in combination with capecitabine | Biostar Pharma, Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Utidelone in combination with capecitabine CI watch — RSS
- Utidelone in combination with capecitabine CI watch — Atom
- Utidelone in combination with capecitabine CI watch — JSON
- Utidelone in combination with capecitabine alone — RSS
Cite this brief
Drug Landscape (2026). Utidelone in combination with capecitabine — Competitive Intelligence Brief. https://druglandscape.com/ci/utidelone-in-combination-with-capecitabine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab